Table 1.
Patient characteristics
| n | 2,863 |
|---|---|
| Age, mean ± SD | 66.71 ± 9.149 |
| Sex (male), n (%) | 1,478 (51.6%) |
| Smoking history, n (%) | 1,471 / 2,779 (52.9%) |
| Procedure, n (%) | |
| Lobectomy | 2,863 (100%) |
| Operation time (min.), mean ± SD | 205.3 ± 66.89 |
| Histological subtype, n (%) | |
| AIS | 135 (4.7%) |
| MIA | 175 (6.1%) |
| Invasive adenocarcinoma | 2,506 (87.5%) |
| Lepidic | 521 (18.2%) |
| Acinar | 537 (18.8%) |
| Papillary | 1,161 (40.6%) |
| Micropapillary | 63 (2.2%) |
| Solid | 224 (7.8%) |
| Variants | 47 (1.6%) |
| Invasion | |
| Lymph vessel invasion ( ±), n (%) | 777 / 1,785 (30.3%) |
| Vascular invasion ( ±), n (%) | 695 / 1,875 (27.0%) |
| Pleural invasion ( ±), n (%) | 691 / 2,156 (24.3%) |
| EGFR status ( ±), n (%) | 641 / 783 (45.0%) |
| Adjuvant chemotherapy ( ±), n (%) | 1,017 / 1,820 (35.8%) |
| Clinical stage, n (%) | |
| Stage IA | 1732 (60.5%) |
| Stage IB | 749 (26.2%) |
| Stage IIA | 190 (6.6%) |
| Stage IIB | 83 (2.9%) |
| Stage IIIA | 98 (3.4%) |
| Pathological stage, n (%) | |
| Stage IA | 1,426 (49.8%) |
| Stage IB | 732 (25.6%) |
| Stage IIA | 260 (9.1%) |
| Stage IIB | 110 (3.8%) |
| Stage IIIA | 314 (11.0%) |
AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, SD standard deviation, Min Minutes